FGF2 and type 1 diabetes mellitus: This study further describes the cell–cell and cell–matrix interactions that promote the differentiation of hO-MSCs into β-cells on the MBP-FGF2 surface, which may provide a new platform for drug screening and cell-based therapies for T1DM.